Surfing the MASH Tsunami
Driving the Discussion in Fatty Liver Disease. Join hepatology researcher and Key Opinion Leader Jörn Schattenberg, Liver Wellness Advocate Louise Campbell, and Forecasting and Pricing Guru Roger Green and a global group of Key Opinion Leaders and patient advocates as they discuss key issues in Fatty Liver disease, including epidemiology, drug development, clinical pathways, non-invasive testing, health economics and regulatory issues, from their own unique perspectives on the Surfing the MASH Tsunami podcast. #MASH #MAFLD #FattyLiver #livertwitter #AASLD #GlobalLiver #NoNASH #EASL
- Update frequency
- every day
- Average duration
- 26 minutes
- Episodes
- 1069
- Years Active
- 2020 - 2025
International NASH Day is Here! - Ep 9
Surfing the NASH Tsunami celebrates a growing and increasingly important global event for the Fatty Liver community.
Global Liver Institute President & CEO Donna Cryer joins the Surfers …
Diagnosing Diagnostics – Part I - Ep 8
Room for improvement
GenFit Head of Global Diagnostics Suneil Hosmane joins the Surfers in exploring the current strengths and drawbacks of Fatty Liver diagnostics. The conversation cons…
NASH-Ville - Part 2: Better Days Ahead? - Ep 7
Reviewing press releases reporting preliminary findings from six recently announced Phase 2 trials
Stephen Harrison leads the Surfers, with guest Louise Campbell, through an examination …
What’s in a Name: NAFLD or MAFLD? - Ep 6
Exploring the controversy over the name(s) to use when describing Fatty Liver disease(s)
Professor Quentin Anstee joins the Surfers for a thoughtful consideration of the factors that sho…
Wild Times In NASH-Ville – Part I - Ep 5
Clinical trial results that are changing how we look at NASH
Stephen Harrison leads a review of two recent Phase 3 data statements: the outcome of GenFit’s RESOLVE-IT trial and Madrigal …
When You Get To A Fork In The Road - Ep 4
Three possible scenarios for development of the NASH market.
Roger Green presents three possible directions for the NASH market over the next 5-10 years and asks our panelists, including…
C-Suite COVID-19 Challenges - Ep 3
Critical considerations for companies developing NASH drugs
Peter Traber focuses on ways COVID-19 can affect drug development and broader corporate strategies while our panelists weigh i…
Five $imple Pieces - Ep 2
What investors want to know about NASH development during the pandemic.
Yasmeen Rahimi poses five questions NASH investors ask her about the impact of COVID-19 on NASH clinical and comme…
COVID CHAOS - Ep 1
Navigating NAFLD/NASH clinical trials through the pandemic
Dr. Stephen Harrison discusses several ways the pandemic is affecting planning and execution of clinical trials and our panelis…